A cornerstone of the 2022 Inflation Reduction Act carries into 2027: a firm ceiling on what a Medicare drug plan member pays out of pocket for covered prescriptions in a single year. For 2027 that cap is set near $2,400, and once a beneficiary’s spending reaches it, covered drugs cost nothing for the rest of the calendar year. The protection is worth the most to the retirees with the highest pharmacy bills, the ones who used to face thousands of dollars in open-ended costs before the cap existed.
How the $2,400 ceiling works in 2027
The annual out-of-pocket limit on covered Part D drugs is scheduled to rise to about $2,400 for 2027, up from $2,100 in 2026. Once a member’s spending on covered medications hits that figure, the plan pays the full cost of covered drugs for the remainder of the year, ending the era when a person with serious illness could spend without any upper bound.
The cap replaced the old coverage gap, the so-called donut hole, that once left beneficiaries paying a large share of drug costs in a middle spending range. A separate deductible still applies at the start of the year before the plan begins sharing costs, and that deductible is set higher for 2027, so early-year spending can feel steep even as the yearly ceiling protects the total.
For 2027 that starting deductible is set at $700, up from $615 in 2026, so a member covers the first stretch of drug costs before the plan’s share begins. Under the redesigned benefit, spending now moves through three phases in a year rather than four: the deductible phase, an initial phase in which the member pays a share of each drug, and a final phase that begins once the out-of-pocket total reaches the cap, after which covered drugs are free. Erasing the old fourth stage, the coverage gap, is what makes the yearly ceiling a hard stop rather than a temporary reprieve.
The mechanism matters most for enrollees on high-cost specialty medications, where a single prescription can carry a list price in the thousands. For those members, reaching the cap early in the year and paying nothing afterward can mean the difference between filling a prescription and skipping it.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
Insulin stays capped at $35 a month
Alongside the yearly ceiling, covered insulin remains capped at $35 for a one-month supply in 2027, with no deductible applied first. That limit holds regardless of how far a member is from the broader out-of-pocket cap, so the price of a covered insulin product does not swing month to month the way it did before the rule took effect.
For a diabetic retiree who once paid several times that amount, the difference over a year is substantial. The Medicare cost rules apply the $35 figure per covered insulin, meaning a person taking more than one covered product pays the capped amount on each rather than a single blended charge.
Recommended adult vaccines under Part D also carry no cost-sharing, a related benefit that sits outside the deductible and cap alike. Shingles, RSV and other vaccines that once triggered a copay now arrive at no charge for enrollees, another piece of the same law.
Negotiated prices now lower what counts toward the cap
A second piece of the same 2022 law began delivering savings in 2026, when Medicare’s first directly negotiated drug prices took effect. For an initial list of ten of the highest-spending Part D medications, among them the blood thinner Eliquis and the diabetes drug Januvia, the negotiated prices cut the cost of a month’s supply sharply, with reductions running from roughly 38% to 79% against earlier list prices.
Those lower prices interact directly with the out-of-pocket ceiling. Because a beneficiary reaches the cap based on what is actually spent on covered drugs, a cheaper negotiated price can mean a member takes longer to hit the $2,400 limit, but each fill along the way costs less. A second, larger group of drugs is scheduled for negotiated prices in the years ahead, extending the reach of the program to more of the medications retirees rely on.
The Medicare Prescription Payment Plan spreads the cost
Reaching a $2,400 ceiling still means paying up to that amount, and for some members the timing is the problem: a large bill early in the year can arrive before a fixed monthly income can absorb it. The Medicare Prescription Payment Plan addresses that by letting enrollees spread out-of-pocket drug costs into level monthly installments across the year rather than paying each pharmacy bill in full at the counter.
The option does not lower the total a person owes; it smooths when the money is paid. A member who expects high drug costs concentrated in the first months of the year may benefit most, while someone with modest, steady spending may find little advantage in it. Enrollment is voluntary and can be requested through the drug plan.
Taken together, the annual cap, the insulin limit and the payment plan reshape how retirees encounter drug costs under Medicare. The ceiling ends the fear of unlimited spending, the insulin rule steadies a recurring expense, and the installment option keeps a big early bill from crowding out other necessities, a combination that rewards checking a plan’s numbers before the next enrollment season closes.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
More Financial Reading
